Halper Sadeh LLC is launching an investigation into the fairness of the proposed sale of 89bio, Inc. to Roche, scrutinizing whether the offered price adequately reflects the company’s value for its shareholders.
NEW YORK–(BUSINESS WIRE)–Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of 89bio, Inc. (NASDAQ: ETNB) to Roche is fair to 89bio shareholders. Under the terms of the proposed transaction, 89bio shareholders will receive $14.50 per share in cash at closing, plus a non-tradeable contingent value right to receive certain contingent payments of up to an aggregate of $6.00 per share in cash upon achievement of specified milestones. Halper Sadeh encourages 89bio sha
Source: Original Press Release
